Filing Details

Home > Insider Trading > Latest 13D and 13G Filings > 13G Filing (0001193125-22-230026)

NAMES OF REPORTING PERSONS

Pivotal bioVenture Partners Fund I, L.P.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☒

SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

Accession Number:: 0001193125-22-230026
Form Type:: 13G Filing
Publication Date:: 2022-08-24 20:00:00

Filed By:: Pivotal Bioventure Partners Fund I, L.p.
Company:: Akouos Inc. (NASDAQ:AKUS)
Filing Date:: 2022-08-25
SEC Url:: 13G Filing

Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name	Shared Voting Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Pivotal bioVenture Partners Fund I	1,794,088	1,794,088	1,794,088	4.9%
Pivotal bioVenture Partners Fund I G.P.	1,794,088	1,794,088	1,794,088	4.9%
Pivotal bioVenture Partners Fund I U.G.P., Ltd	1,794,088	1,794,088	1,794,088	4.9%
Pivotal Partners Ltd	1,794,088	1,794,088	1,794,088	4.9%
Pivotal Life Sciences Holdings Limited	1,794,088	1,794,088	1,794,088	4.9%
Nan Fung Group Holdings Limited	1,794,088	1,794,088	1,794,088	4.9%
NF Investment Holdings Limited	1,794,088	1,794,088	1,794,088	4.9%
Nan Fung Life Sciences Holdings Limited	1,794,088	1,794,088	1,794,088	4.9%
NFLS Beta Limited	1,794,088	1,794,088	1,794,088	4.9%
NFLS Platform Holdings Limited	1,794,088	1,794,088	1,794,088	4.9%

Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Akouos, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

00973J101

(CUSIP Number)

August 25, 2022

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Item 1(a).

Name of Issuer:

Akouos, Inc. (the Issuer)

Item 1(b).

Address of Issuers Principal Executive Offices:

645 Summer Street, Suite 200

Boston, MA 02210

Item 2(a).

Names of Persons Filing:

The name of the persons filing this report (the Reporting Persons) are:

(i)

Pivotal bioVenture Partners Fund I, L.P. (Pivotal)

(ii)

Pivotal bioVenture Partners Fund I G.P., L.P. (Pivotal GP)

(iii)

Pivotal bioVenture Partners Fund I U.G.P., Ltd. (the Ultimate General Partner)

(iv)

Pivotal Partners Ltd (Pivotal Partners)

(v)

Pivotal Life Sciences Holdings Limited (Pivotal Life Sciences)

(vi)

Nan Fung Group Holdings Limited (NFGHL)

(vii)

NF Investment Holdings Limited (NFIHL)

(viii)

Nan Fung Life Sciences Holdings Limited (Nan Fung Life Sciences)

(ix)

NFLS Beta Limited

(x)

NFLS Platform Holdings Limited

Item 2(b).

Address of Principal Business Office or, if None, Residence:

The address of the principal business office of Pivotal, Pivotal GP and the Ultimate General Partner is:

501, Second Street, Suite 200

San Francisco, CA 94107

The registered office address of Pivotal Partners and Pivotal Life Sciences is:

Cricket Square, Hutchins Drive, PO Box 2681, Grand Cayman, KY1-1111, Cayman Islands

The address of the principal business office of NFGHL is:

23^rd Floor, Nan Fung Tower,

88 Connaught Road C & 173 Des Voeux Road C, Central, Hong Kong.

The registered office address of NFIHL is:

Vistra Corporate Services Centre, Wickhams Cay II,

Road Town, Tortola, VG1110, British Virgin Islands.

Item 2(c).

Citizenship:


		Pivotal		Cayman Islands

		Pivotal GP		Cayman Islands

		The Ultimate General Partner		Cayman Islands

		Pivotal Partners		Cayman Islands



		Pivotal Life Sciences		Cayman Islands

		NFGHL		British Virgin Islands

		NFIHL		British Virgin Islands

		Nan Fung Life Sciences		British Virgin Islands

		NFLS		British Virgin Islands

		NFLS Platform		Cayman Islands

Item 2(d).

Title of Class of Securities:

Common Stock, par value $0.0001 (Common Stock)

Item 2(e).

CUSIP Number:

00973J101

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4.

Ownership.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages are based on 36,899,235 outstanding shares of Common Stock as reported in the Issuers Form 10-Q filed August 15, 2022.

Pivotal directly holds 1,794,088 shares of Common Stock. Pivotal GP is the general partner of Pivotal. The Ultimate General Partner is the general partner of Pivotal GP. The Ultimate General Partner is wholly-owned by Pivotal Partners. Pivotal Partners is wholly-owned by Pivotal Life Sciences. Pivotal Life Sciences is wholly-owned by Nan Fung Life Sciences, and Nan Fung Life Sciences is wholly owned by NFIHL, which is wholly owned by NFGHL. The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Mr. Kin Ho Kwok, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL.

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certification.

Not applicable.

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: August 25, 2022


PIVOTAL BIOVENTURE PARTNERS FUND I, L.P.

By: PIVOTAL BIOVENTURE PARTNERS FUND I G.P., L.P.
Its General Partner,

By: PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P., LTD.
Its General Partner,

By:		/s/ Robert Hopfner
		Robert Hopfner
		Authorized Signatory

PIVOTAL BIOVENTURE PARTNERS FUND I G.P., L.P.

By: PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P., LTD
Its General Partner,

By:		/s/ Robert Hopfner
		Robert Hopfner
		Authorized Signatory

PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P., LTD.

By:		/s/ Robert Hopfner
		Robert Hopfner
		Authorized Signatory

PIVOTAL PARTNERS LTD

By:		/s/ Sun Xintong
Name:		Sun Xintong
Title:		Director

PIVOTAL LIFE SCIENCES HOLDINGS LIMITED

By:		/s/ Sun Xintong
Name:		Sun Xintong
Title:		Director


NAN FUNG GROUP HOLDINGS LIMITED

By:		/s/ Tang Chun Wai Nelson
		Tang Chun Wai Nelson
		Director

NF INVESTMENT HOLDINGS LIMITED

By:		/s/ Tang Chun Wai Nelson
		Tang Chun Wai Nelson Director

NAN FUNG LIFE SCIENCES HOLDINGS LIMITED

By:		/s/ Sun Xintong
		Sun Xintong Director

NFLS BETA LIMITED

By:		/s/ Sun Xintong
		Sun Xintong Director

NFLS PLATFORM HOLDINGS LIMITED

By:		/s/ Sun Xintong
		Sun Xintong Director